Modulating dendritic cells to optimize mucosal immunization protocols

Journal of Immunology

Volumn 163, Issue 7, 1999, Pages 3668-3675

  Williamson, Eilidh ^a   Westrich, Gina M ^a   Viney, Joanne L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; B7 ANTIGEN; CD86 ANTIGEN; CHOLERA TOXIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNIZATION; INTESTINE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CHOLERA TOXIN; CYTOKINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; IMMUNIZATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTESTINAL MUCOSA; LIGANDS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; PEYER'S PATCHES;

EID: 0033213958     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Mowat, A. M., and J. L. Viney. 1997. The anatomical basis of intestinal immunity. Immunol. Rev. 156:145.
2. Mowat, A. M. 1987. The regulation of immune responses to dietary protein antigens. Immunol. Today 8:93.
3. Weiner, H. L., A. Friedman, A. Miller, S. J. Khoury, A. al-Sabbagh, L. Santos, M. Sayegh, R. B. Nussenblatt, D. E. Trentham, and D. A. Hafler. 1994. Oral tolerance: immunologic mechanisms and treatment of animal and human organ specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12:809.
4. Weiner, H. L. 1997. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today 18:335.
5. Elson, C. O., and W. Ealding. 1984. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 132:2736.
6. Lycke, N., and I. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301.
7. Vajdy, M., and N. Lycke. 1993. Stimulation of antigen-specific T- and B-cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunology 80:197.
8. Holmgren, J., C. Czerkinsky, N. Lycke, and S. A. M. 1992. Mucosal immunity: implications for vaccine development. Immunobiology 184:157.
9. + T cell dependent. Infect. Immun. 59:3630.
10. Holmgren, J., N. Lycke, and C. Czerkinsky. 1993. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11:1179.
11. Elson, C. O., and W. Ealding. 1984. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 133:2892.
12. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clements. 1983. New knowledge on pathogenesis of bacterial enteric infection as applied to vaccine development. Microbiol. Rev. 47:510.
13. Fontana, M. R., R. Manetti, V. Giannelli, C. Magagnoli, A. Marchini, R. Olivieri, M. Domenighini, R. Rappuoli, and M. Pizza. 1995. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:2356.
14. Yamamoto, S., H. Kiyono, M. Yamamoto, K. Imaoka, K. Fujihashi, F. W. Van Ginkel, M. Noda, Y. Takeda, and J. R. McGhee. 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 94:5267.
15. Yamamoto, S., Y. Takeda, M. Yamamoto, H. Kurazono, K. Imaoka, M. Yamamoto, K. Fujihashi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185:1203.
16. Douce, G., M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:2821.
17. Steinman, R. M. 1991. The dendritic cell and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
18. Brasel, K., H. J. McKenna, P. J. Morrissey, K. Charrier, A. E. Morris, C. C. Lee, D. E. Williams, and S. D. Lyman. 1996. Hematologic effects of flt3 ligand in vivo in mice. Blood 88:2004.
19. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953.
20. Viney, J. L., A. M. Mowat, J. M. O'Malley, E. Williamson, and N. A. Fanger. 1998. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J. Immunol. 160:5815.
21. + T cell growth. Int. Immunol. 3:323.
22. Alving, C. R. 1993. Lipopolysaccharide, lipid A and liposomes containing lipid A as immunologic adjuvants. Immunobiology 187:430.
23. Bromander, A., J. Holmgren, and N. Lycke. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146:2908.
24. Lycke, N., A. K. Bromander, L. Ekman, U. Karlsson, and J. Holmgren. 1989. Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant effect in vivo. J. Immunol. 142:20.
25. + TCRlo thymocytes in vivo. Science 250: 1720.
26. Elson, C. O., W. Ealding, and J. Lefkowitz. 1984. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. J. Immunol. Methods 67:101.
27. Vajdy, M., M. H. Kosco-Vilbois, M. Kopf, G. Kohler, and N. Lycke. 1995. Impaired mucosal immune responses in interleukin-4 targeted mice. J. Exp. Med. 181:41.
28. Kearney, E. R., K. A. Pape, D. Y. Loh, and M. K. Jenkins. 1994. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1:327.
29. Garside, P., M. Steel, E. A. Worthey, A. Satoskar, J. Alexander, H. Bluethmann, F. Y. Liew, and A. M. Mowat. 1995. T helper 2 cells are subject to high dose oral tolerance and are not essential for its induction. J. Immunol. 154:5649.
30. McGee, J. R., J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, J. H. Hirasawa, and H. Kiyono. 1992. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10:75.
31. Lycke, N., A. K. Bromander, and J. Holmgren. 1989. Role of local IgA antitoxin-producing cells for intestinal protection against cholera toxin challenge. Int. Arch. Allergy Appl. Immunol. 88:273.
32. O'Doherty, U., M. Peng, S. Gezelter, W. J. Swiggard, M. Betjes, N. Bhardwaj, and R. M. Stemman. 1994. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 82:487.
33. Zhou, L.-J., and T. F. Tedder. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154: 3821.
34. Van Houten, N., and S. F. Blake. 1996. Direct measurement of anergy of antigen-specific T cells following oral tolerance induction. J. Immunol. 157:1337.
35. Samoilova, E. B., J. L. Horton, H. Zhang, S. J. Khoury, H. L. Weiner, and Y. Chen. 1998. CTLA-4 is required for the induction of high dose oral tolerance. Int. Immunol. 10:491.
36. Perez, V. L., L. Van Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411.
37. Cong, Y., C. T. Weaver, and C. O. Elson. 1997. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 159:5301.
38. McGee, D. W., C. O. Elson, and J. R. McGee. 1993. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect. Immun. 61:4637.
39. Staats, H. F., and F. A. Ennis, Jr. 1999. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J. Immunol. 162:6141.
40. Varilek, G. W., G. A. Neil, and W. P. Bishop. 1994. Caco-2 cells express type 1 interleukin-1 receptors: ligand binding enhances proliferation. Am. J. Physiol. 267:G1101.
41. Mowat, A. M., A. K. Hutton, P. Garside, and M. A. Steel. 1993. A role for interleukin 1α in immunologically mediated enteropathy. Immunology 80:110.
42. Staruch, M. J., and D. D. Wood. 1983. The adjuvanticity of interleukin 1 in vivo. J. Immunol. 130:2191.
43. Nencioni, L., L. Villa, A. Tagliabue, G. Antoni, R. Presentini, F. Perin, S. Silvestri, and D. Boraschi. 1987. In vivo immunostimulatory activity of the 163-171 peptide of human IL-1B. J. Immunol. 139:800.
44. Tagliabue, A., and D. Boraschi. 1993. Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide 163-171. Vaccine 11:594.
45. Pike, B. L., and G. J. V. Nossal. 1985. Interleukin 1 can act as a B cell growth and differentiation factor. Proc. Natl. Acad. Sci. USA 82:8153.
46. Chiplunkar, S., J. Langhorne, and S. H. E. Kaufmann. 1986. Stimulation of B cell growth and differentiation by murine recombinant interleukin 1. J. Immunol. 137:37.